Adjuvant Chemotherapy Use for Hormone Receptor–Positive, -Negative Breast Cancer After RxPONDER Trial

What are the patterns of adjuvant chemotherapy use for early-stage hormone receptor (HR)–positive, negative breast cancer by genomic risk and nodal status?In this cohort study of 504 937 women, adjuvant chemotherapy use nearly doubled in premenopausal patients with node-positive tumors and low or intermediate 21-gene recurrence score from 2019 to 2022 but decreased for women with node-negative disease.The findings highlight the variability in genomic assay use to inform adjuvant systemic therapy recommendations in HR-positive, -negative breast cancer.

Corresponding Authors: Poornima Saha, MD, Division of Hematology and Oncology, Department of Medicine, Endeavor Health, 2650 Ridge Ave, Evanston, IL 60201 (poornima.saha@endeavorhealth.org); Frederick M. Howard, MD, Section of Hematology and Oncology, Department of Medicine, The University of Chicago, 5758 S Maryland Ave, Chicago, IL 60637 (frederick.howard@bsd.uchicago.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.